Compare
Revium Rx. vs GT Biopharma, Inc. vs Palatin Technologies Inc vs CNS Pharmaceuticals, Inc.
| Latest fiscal year | Revium Rx. RVRC | GT Biopharma, Inc. GTBP | Palatin Technologies Inc PTN | CNS Pharmaceuticals, Inc. CNSP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | n/a | $13.19M | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -65.7% | n/a |
| Net margin | n/a | n/a | -63.5% | n/a |
| Net income | -$13.45M | -$28.35M | -$8.38M | -$15.85M |
| EPS (Diluted) | -$0.22 | -$6.68 | -$2.96 | -$35.75 |
| Operating cash flow | n/a | -$12.91M | -$13.53M | -$13.81M |
| Free cash flow | n/a | n/a | -$13.58M | -$13.83M |
| Cash & equivalents | $1.68M | $6.81M | $7.49M | $7.20M |
| Total assets | $8.30M | $8.11M | $8.52M | $8.62M |
| Total liabilities | $1.42M | n/a | $1.84M | $4.10M |
| Shareholders' equity | $6.88M | $5.79M | $6.69M | $4.52M |
| Return on year-end equity | -195.5% | -490.0% | -125.3% | -350.5% |
| Shares outstanding | 60.73M | 25.53M | 1.78M | 632.5K |
Revenue, most recent five fiscal years
| Fiscal year | Revium Rx. | GT Biopharma, Inc. | Palatin Technologies Inc | CNS Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2020-12-31 | $13.19M Ended 2026-06-30 | n/a |
| 1 year earlier | n/a | $0 Ended 2019-12-31 | n/a | n/a |
| 2 years earlier | n/a | n/a | n/a | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |